TE-1182 is an ADC developed using the CHO-TEM technology platform jointly established by CHO Pharma and T-E Meds.
Its antibody component consists of a full-length IgG molecule, specifically trastuzumab (TRZ), which is produced and glycosylated by CHO Pharma. TRZ is a humanized anti-HER2 IgG monoclonal antibody designed to precisely targets cancer cells that overexpress the HER2 gene on their surface.
Leveraging site-specific conjugation technology, this IgG can be conjugated to 4 drug bundles developed by T-E Meds. Each drug bundle carries two distinct cytotoxic molecules, MMAF and Exatecan (EXT), meaning that each TRZ antibody is conjugated to 4 molecules of MMAF and 4 molecules of EXT. When TRZ specifically targets cancer cells, the cytotoxic molecules are released from the drug bundles, effectively destroying the cancer cells.
Notably, TE-1182 is a homogeneous ADC product with a defined drug-to-antibody ratio (DAR) of 8, exhibiting superior stabilities in vitro and in vivo.
The molecular structure of TE-1182.
In cytotoxicity assays conducted across four tumor cell lines with varying levels of HER2 expression — high (SKBR3 breast cancer cells and NCI-N87 gastric cancer cells), moderate with Enhertu resistance (JIMT-1 breast cancer cells), and low (MDA-MB-361 breast cancer cells) — TE-1182 consistently demonstrated superior cytotoxic activity compared to Enhertu, highlighting its therapeutic potential in overcoming the challenges of HER2 heterogeneity and drug resistance.
In a JIMT-1 cell line-derived xenograft (CDX) model established in SCID mice, TE-1182 was administered Q7D (once every 7 days) for four doses. The results demonstrated that TE-1182 exhibited superior in vivo tumor inhibition compared with Enhertu, with no tumor regrowth observed up to day 63.